Mayne Pharma Group Ltd (ASX: MYX) Share Price and News
Price
Movement
52 Week Range
1 Year Return
() Chart and Price Data
Mayne Pharma Group Ltd (ASX: MYX) Latest News
Why the Mayne Pharma (ASX:MYX) share price is pushing higher
James Mickleboro | January 7, 2021 10:16am
Mayne Pharma (ASX:MYX) share price falls on results update
Eddy Sunarto | November 24, 2020 10:57am
2 ASX healthcare shares that have risen since Pfizer’s vaccine news
Miles Wu | November 12, 2020 10:58am
Mayne Pharma (ASX:MYX) share price dives 16% on FDA update
Aaron Teboneras | October 6, 2020 1:36pm
Why IAG, Mayne Pharma, Mesoblast, & Temple & Webster shares are tumbling lower
James Mickleboro | October 6, 2020 11:18am
The Mayne Pharma (ASX:MYX) share price leaps almost 8% higher
Bernd Struben | September 14, 2020 4:50pm
Why IDP Education, IRESS, Mosaic Brands, & Mayne Pharma are dropping lower
James Mickleboro | August 21, 2020 12:46pm
Recent Stock Announcements
| Date | Heading | An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. | Time | Pages | File Size |
|---|---|---|---|---|---|
About Mayne Pharma Group Ltd (ASX: MYX)
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company that applies its drug delivery expertise to commercialise branded and generic pharmaceuticals. The company also provides contract development and manufacturing services to more than 100 clients worldwide.
Mayne Pharma is technology driven with a significant product portfolio and pipeline, and global reach through distribution partners in Australia, North America, Europe and Asia. The company has product development and manufacturing facilities in Salisbury, Australia and Greenville, North Carolina, USA with expertise in formulating complex oral and topical dose forms. The business is supported by more than 900 staff globally with more than 200 scientists employed.
The Salisbury facility is capable of developing products from formulation and clinical trial stages to validation and registration, right through to commercial scale manufacture of packaged goods.
Director Transactions
Data provided by Morningstar.Directors & Management
Data provided by Morningstar.Top Share Holders
Data provided by Morningstar.| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 320,478,060 | 19.10% |
| Mr Bruce Mathieson And Related Entities | 105,577,583 | 6.30% |
| J P Morgan Nominees Australia Pty Limited | 102,531,522 | 6.10% |
| Citicorp Nominees Pty Limited | 97,467,463 | 5.80% |
| Solium Nominees (Australia) Pty Ltd <Bare Allocated A/C> | 89,184,990 | 5.30% |
| Estetra Sprl | 83,100,000 | 4.90% |
| Solium Nominees (Australia) Pty Ltd <Unallocated A/C> | 29,692,951 | 1.80% |
| BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 26,688,048 | 1.60% |
| IVL Group Pty Ltd | 16,000,000 | 1.00% |
| BNP Paribas Noms Pty Ltd <Drp> | 14,106,094 | 0.80% |
| Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 14,100,000 | 0.80% |
| Australian Executor Trustees Limited <Ips Super A/C> | 11,327,284 | 0.70% |
| Mr Roger Corbett And Related Entities | 10,440,569 | 0.60% |
| National Nominees Limited | 10,278,401 | 0.60% |
| Vivnat (Curtin) Pty Ltd | 10,000,000 | 0.60% |
| Y S Chains Pty Ltd | 10,000,000 | 0.60% |
| WAL Assets Pty Ltd <The La Wilson Property A/C> | 9,193,503 | 0.50% |
| R & J Smith Shareholding Pty Ltd <R & J Smith Shareholding A/C> | 8,853,084 | 0.50% |
| Mr Roger Aston & Related Entities | 7,140,935 | 0.40% |
| William P Hodges | 6,089,554 | 0.40% |